Case report: Oseltamivir-induced resistant pandemic influenza A (H1N1) Virus infection in a patient with AIDS and Pneumocystis jirovecii pneumonia

Journal of Medical Virology

Volumn 85, Issue 6, 2013, Pages 941-943

  Van Kampen, Jeroen J A ^a   Bielefeld Buss, Astrid J ^b   Ott, Alewijn ^b   Maaskant, Jolanda ^a   Faber, Harald J ^c   Lutisan, Johan G ^c   Boucher, Charles A B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Laboratory for Infectious Diseases   (Netherlands)

^c Wilhelmina Ziekenhuis   (Netherlands)

Author keywords

HIV; Influenza; Oseltamivir; Pneumocystis; Resistance

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; LEVOFLOXACIN; OSELTAMIVIR; PREDNISONE; ZANAMIVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); LUNG LAVAGE; MALE; MIXED INFECTION; PNEUMOCYSTIS PNEUMONIA; THORAX RADIOGRAPHY;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE; PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECII;

EID: 84876353417     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23560     Document Type: Article

References (13)

1. Alonso M, Rodríguez-Sánchez B, Giannella M, Catalán P, Gayoso J, López Bernaldo de Quirós JC, Bouza E, García de Viedma D. 2011. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol 50: 114-118.
2. Centers for Disease Control and Prevention. 2009. Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients-Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 58: 893-896.
3. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C. 2010. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: A randomized placebo-controlled trial. PLoS Med 7: e1000362.
4. Fraaij PL, van der Vries E, Beersma MF, Riezebos-Brilman A, Niesters HG, van der Eijk AA, de Jong MD, Reis Miranda D, Horrevorts AM, Ridwan BU, Wolfhagen MJ, Houmes RJ, van Dissel JT, Fouchier RA, Kroes AC, Koopmans MP, Osterhaus AD, Boucher CA. 2011. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 204: 777-782.
5. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC. 2009. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 199: 1435-1441.
6. Graitcer SB, Gubareva L, Kamimoto L, Doshi S, Vandermeer M, Louie J, Waters C, Moore Z, Sleeman K, Okomo-Adhiambo M, Marshall SA, St George K, Pan CY, LaPlante JM, Klimov A, Fry AM. 2011. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 17: 255-257.
7. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI. 2010. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 15: 1151-1159.
8. Meijer A, Jonges M, Abbink F, Ang W, van Beek J, Beersma M, Bloembergen P, Boucher C, Claas E, Donker G, van Gageldonk-Lafeber R, Isken L, de Jong A, Kroes A, Leenders S, van der Lubben M, Mascini E, Niesters B, Oosterheert JJ, Osterhaus A, Riesmeijer R, Riezebos-Brilman A, Schutten M, Sebens F, Stelma F, Swaan C, Timen A, van 't Veen A, van der Vries E, te Wierik M, Koopmans M. 2011. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands 2009-2010. Antiviral Res 92: 81-89.
9. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. 2010. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 50: 1252-1255.
10. Ormsby CE, de la Rosa-Zamboni D, Vázquez-Pérez J, Ablanedo-Terrazas Y, Barrientos R, Gómez-Palacio M, Murakami-Ogasawara A, Ibarra-Ávalos JA, Rodríguez D, Avila-Ríos S, Reyes-Terán G. 2011. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. AIDS 25: 435-439.
11. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM, US Antiviral Resistance Surveillance Working Group. 2012. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 18: 308-311.
12. Tramontana AR, George B, Hurt AC, Doyle JS, Langan K, Reid AB, Harper JM, Thursky K, Worth LJ, Dwyer DE, Morrissey CO, Johnson PD, Buising KL, Harrison SJ, Seymour JF, Ferguson PE, Wang B, Denholm JT, Cheng AC, Slavin M. 2010. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 16: 1068-1075.
13. van der Vries E, Stelma FF, Boucher CA. 2010. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382.